MedTrace Logo

Radiogenomics of Muscle Invasive Bladder Cancer

NCT04806334 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-04-18

Study results available
· View outcomes & findings →

Summary

Patients with suspected bladder tumor will undergo novel 4D MRI imaging along with single cell RNA sequencing in hopes of identifying a radiogenomic signature that can improve our staging of patients with muscle invasive bladder cancer.

Conditions

  • Bladder Cancer Stage II

Interventions

DIAGNOSTIC_TEST

MRI imaging of the pelvis/bladder

The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).

DIAGNOSTIC_TEST

genomic analysis of tumor

Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Charles J Rosser, MD · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-02
Primary Completion
2023-09-09
Completion
2024-04-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04806334 on ClinicalTrials.gov